Who we are?

Pharmaseed is a GLP-certified pre-clinical and early clinical CRO specializing in translational and regenerative studies.

Founded in 2003, Pharmaseed is a GLP-certified CRO providing preclinical, early clinical, and consulting services to biotech, pharma, and medical device companies. We operate advanced laboratories and a high-quality vivarium to deliver reliable, decision-ready data.

We operate in Israel and the United States to support global clients with efficient collaboration and U.S. partner alignment. This further enhances our ability to facilitate the seamless transformation of innovative ideas into tangible, market-ready health solutions.

Clients choose us for rigorous GLP execution, multidisciplinary capabilities, and practical guidance from study design through interpretation. We deliver high-quality services with cost-efficient execution compared with many U.S. and European CROs.

Programs:

Pharmaceuticals, biologics, and medical devices (to first-in-human readiness)

Capabilities:

in-vivo, ex-vivo, in-vitro, human anatomy services

Core areas:

Cardiovascular, immuno-oncology, cell therapies, microbiome and infectious diseases, and CNS

Why work with Pharmaseed?

Israel’s largest GLP-certified preclinical and early clinical CRO, focused on translational programs from early studies to first-in-human readiness.
Over 20 years of experience with a multidisciplinary team, including 13+ PhD/postdoc-level scientists with industry backgrounds.
In-house vivarium, BSL-2 unit, and modern in-vitro labs - executing complex studies across molecular, cellular, and in-vivo systems under strict ethical and regulatory standards.

We combine flexible problem-solving with strict GLP quality, documentation, and ethical standards.
We support the full R&D cycle: study design, execution, and data interpretation, helping teams make faster, higher-confidence go/no-go decisions, multiplying the chances of transforming your product from a mere idea, to a real sustainable technology.
Safety & ADME (GLP) expertise - Nonclinical toxicity and ADME studies supporting IND/CTA-enabling packages and development decisions